Twitter Beğeni Hilesi

EORTC is pleased to announce that the phase III EORTC-1333-GUCG/PEACE III trial database is locked. It reached data maturity for its primary endpoint (radiological progression free survival) and analysis has started. eortc.org/blog/2024/06/2… @Silke_Gillesse tombal

🌟Great discussion at the XXI MaNGO meeting on new targets and new drugs for the treatment of ovarian cancer. 🇮🇹It is always so nice to meet italian friends and colleagues, learn from each other and bring the IOSI experience. Ente Ospedaliero Cantonale Istituto Mario Negri

Is There a Place for De-escalating Therapy in Patients with Metastatic...The answer is clinical trials.... silke gillessen Fabio Turco aurelius omlin Advanced Prostate Cancer Consensus Conference EORTC GUCG YI EORTC sciencedirect.com/science/articl…

We will discuss this important topic also GETUG this week

GETUG tombal silke gillessen Great panel! 👏GETUG

Great 1. Day #urotrials meeting - kudos to Marc-Oliver Grimm for setting this up 👋 OncoAlert Advanced Prostate Cancer Consensus Conference Tom Powles

Excited to share results from our successful phase 2 The PCCTC trial STARTAR: salvage RT w/ chemohormonal triple tx in high risk PSA relapse post RP. Phase 3 next! sciencedirect.com/science/articl… European Urology Oncology Tian Zhang, MD, MHS Dan George DCI Center for Prostate & Urologic Cancers Scott Tagawa Wake Forest University School of Medicine

Compliments Yüksel, very well deserved!

Congrats Heather & team!

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive #ProstateCancer out on ACS Journal Cancer Study analyzed the epidemiology, clinical outcomes, and treatment patterns of de novo oligometastatic hormone-sensitive prostate cancer

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities onlinelibrary.wiley.com/doi/abs/10.100… Study aimed to assess the relative burden of #ProstateCancer specific mortality (PCSM) across different risk

EAU-EANM- ESTRO -ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent out on European Urology europeanurology.com/article/S0302-… The 2024 European Association of Urology European Association of Urology (EAU) guidelines on clinically localized

Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis out on Radiology pubs.rsna.org/doi/10.1148/ra… Study systematically reviewed and analyzed 70 studies to assess the diagnostic performance of the Prostate

#prostatecancer a 🧵 I’ve been told “at least you got the good cancer to get” so I thought I’d do a 🧵 about what a stage 4 incurable cancer is really like and the impact on life. Let’s start with the treatment for it which the mainstay of is removal of male hormone 1/

Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer out on Cancer Research aacrjournals.org/cancerres/arti… Study explores how systemic metabolism, particularly through a high-fat diet (HFD) rich in saturated

Compliments and thanks for being one of our excellent panellists for Advanced Prostate Cancer Consensus Conference

Very interesting data for the important question how to best select patients for therapy with 177Lu-PSMA-617. Compliments to the team Ken Herrmann Andrew Armstrong et al! Will be discussed in detail Advanced Prostate Cancer Consensus Conference Diagnostics in 2025

We need to discuss some of the clichés used in this video as well! But for sure this will be an outstanding event, “first in class” with two really cool moderators that I will expect to turn up in red T-shirts with a big white plus on it…

Just to clarify it was with postoperative radiotherapy not after. And postoperative radiotherapy could be adjuvant or early salvage. So not always easy to extrapolate. I agree completely with the conclusion of the paper that we need more data for patients at high-risk of relapse.

Great summary: there will be some interesting work on potentially predictive markers presented at #ESMO24 Also food for discussion at Advanced Prostate Cancer Consensus Conference in 2025 and 2026!